Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Medtronic
Mallinckrodt
Moodys
Boehringer Ingelheim

Last Updated: June 29, 2022

Details for Patent: 9,233,115


✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,233,115 protect, and when does it expire?

Patent 9,233,115 protects NINLARO and is included in one NDA.

This patent has thirty-nine patent family members in thirty countries.

Summary for Patent: 9,233,115
Title:Proteasome inhibitors and methods of using the same
Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.
Inventor(s): Bernardini; Raffaella (Calci, IT), Bernareggi; Alberto (Concorezzo, IT), Cassara; Paolo G. (Monza, IT), Chatterjee; Sankar (Wynnewood, PA), D'Arasmo; Germano (Novate Milanese, IT), De Munari; Sergio (Milan, IT), Ferretti; Edmondo (Ravenna, IT), Iqbal; Mohamed (Malvern, PA), Menta; Ernesto (Cemusco sul Naviglio, IT), Messina McLaughlin; Patricia A. (Glen Mills, PA), Oliva; Ambrogio (Saronno, IT)
Assignee: Millennium Pharmaceuticals Inc. (Cambridge, MA)
Application Number:13/949,346
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,233,115

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa NINLARO ixazomib citrate CAPSULE;ORAL 208462-001 Nov 20, 2015 RX Yes No See Plans and Pricing See Plans and Pricing USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY See Plans and Pricing
Takeda Pharms Usa NINLARO ixazomib citrate CAPSULE;ORAL 208462-002 Nov 20, 2015 RX Yes No See Plans and Pricing See Plans and Pricing USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY See Plans and Pricing
Takeda Pharms Usa NINLARO ixazomib citrate CAPSULE;ORAL 208462-003 Nov 20, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,233,115

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 045381 See Plans and Pricing
Argentina 095249 See Plans and Pricing
Austria 438650 See Plans and Pricing
Australia 2004268946 See Plans and Pricing
Brazil PI0413582 See Plans and Pricing
Canada 2535686 See Plans and Pricing
China 102603781 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
AstraZeneca
Johnson and Johnson
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.